<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-115506</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">C-Reactive protein and homocysteine in postmenopausal women treated with tibolone</dc:title>
<dc:description xml:lang="en">Objective. To determine modifications in C-reactive protein and homocysteine in postmenopausal women who used tibolone. Materials and methods. We selected a sample of 45 postmenopausal women treated with a 2.5-mg dose of tibolone daily for 6 months. Serum concentrations of C-reactive protein and homocysteine were measured. Results. C-reactive protein concentrations were significantly increased after 6 months of treatment (0.51 ± 0.29 mg/dl at baseline compared with 0.95 ± 0.34 mg/dl after treatment; P&lt;.05). Homocysteine concentrations were significantly reduced after 6 months of treatment (10.16 ± 1.45 picomol/L) compared with initial values (10.95 ± 1.87 picomol/L; P&lt;.05). Conclusions. After 6 months of use, tibolone significantly increased C-reactive protein concentrations and reduced homocysteine concentrations (AU)</dc:description>
<dc:creator>Guerra-Velásquez, Mery</dc:creator>
<dc:creator>Mejia-Montilla, Jorly</dc:creator>
<dc:creator>Santos-Bolívar, Joel</dc:creator>
<dc:creator>Delgado-Delgado, Oneida</dc:creator>
<dc:creator>Torres-Cepeda, Duly</dc:creator>
<dc:creator>Reyna-Villasmil, Nadia</dc:creator>
<dc:creator>Reyna-Villasmil, Eduardo</dc:creator>
<dc:creator>Colmenares-Vega, MAría</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Determinar las modificaciones de la proteína C reactiva y la homocisteína en menopáusicas que utilizan tibolona. Materiales y métodos. Una muestra de 45 menopáusicas que fueron tratadas con una dosis diaria de 2,5 mg de tibolona por 6 meses. Se midieron las concentraciones séricas de proteína C reactiva y homocisteína. Resultados. Se observó un aumento significativo en las concentraciones de proteína C reactiva luego de 6 meses de tratamiento (0,51 ± 0,29 mg/dl al inicio del estudio comparado con 0,95 ± 0,34 mg/dl después del tratamiento; p &lt; 0,05). Se encontró una disminución significativa en las concentraciones de homocisteína cuando se comparó luego de 6 meses de tratamiento (10,16 ± 1,45 pmol/l) con los valores iniciales (10,95 ± 1,97 pmol/l; p &lt; 0,05). Conclusión. La tibolona produjo aumento significativo en las concentraciones de proteína C reactiva y una disminución en las concentraciones de homocisteína luego de 6 meses de uso (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);56(7): 357-361, ago.-sept. 2013.</dc:source>
<dc:identifier>ibc-115506</dc:identifier>
<dc:title xml:lang="es">Proteína C reactiva y homocisteína en menopáusicas tratadas con tibolona</dc:title>
<dc:subject>^d5776^s22073</dc:subject>
<dc:subject>^d10205^s22054</dc:subject>
<dc:subject>^d22243^s22044</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22124^s22044</dc:subject>
<dc:subject>^d6866</dc:subject>
<dc:subject>^d24630^s22039</dc:subject>
<dc:subject>^d22124</dc:subject>
<dc:subject>^d24542</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d24630^s22045</dc:subject>
<dc:subject>^d28608^s22074</dc:subject>
<dc:subject>^d55111^s22021</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d24630^s22074</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d22243^s22021</dc:subject>
<dc:subject>^d5059^s22073</dc:subject>
<dc:subject>^d4634^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
